所有抑酸药物（PPI 和 H2 受体阻滞剂）都被永久禁止；烧心应通过饮食而不是药物来消除。
原始表述
أدوية مثبطات الحموضة ممنوعة عندي بشكل دائم — هي سموم تسبب الكبد الدهني والقولون العصبي، وتمنع الجسم من الاستفادة من الطعام وامتصاص الحديد وفيتامين ب12 والمعادن، وتعالج الأعراض فقط بينما تفاقم المشاكل الأساسية من نمو بكتيري وسوء هضم.
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
所有抑酸药物（PPI 和 H2 受体阻滞剂）都被永久禁止；烧心应通过饮食而不是药物来消除。
出处
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/acid-blockers/
- 归属的不确定性
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. 'Acid suppressants are a deadly poison' (bmiYyChQ310), 'stop them permanently' (MoSROUaIDhs) and 'Controloc is forbidden' (hf_DXalTTDc) are found. H2 blockers were not checked specifically. Other parts of the archive quote (fatty liver, irritable bowel, iron/B12 absorption, bacterial overgrowth) were not found in a single passage with acid suppressants and may be the archive's summary.
- 所声称的机制
Acid is beneficial; suppression is harmful; diet removes the cause.
- 所声称的健康影响
Better health without acid medicines.
- 涉及人群
Everyone following the system.
- Elawady 设定的地域限制
none found
来源版本存在差异
انا في ادويه منعتها قبل ما تقبلني اصلا قلتلك تمنعها نهائي من حياتك ادويه مثبطات الحموضه اللي انتوا كنتوا بتشوهات دي اللي هي بتاخدها الصبح قبل الفطار عشان بعد كده كل اللي يخش جسمك انت مش مستفاد بيه بعد كده اللي يخش جسمك كله مش هيلاقي جهاز مناعه شغال بعد كده كل الحديد اللي انت بتاخديه كل فيتامين بي 12 اللي بتاخديه مش هيمتس ما كنتش عارفين ليه ما كنتش عارفين شعركم بيقع عليه وانتم بتاخدوا الكنترلوك او النكس يا ما كنتش عارفين ان مثبطات الحموضه دي بتمنع امتصاص كل المعادن اصلا
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- الادوية دورها انها تلحقك مش دورها انك تعيش عليها (打开来源)
- 发布日期
- 2024年4月2日
- 时间戳
- 无（转录文本不含时间信息）
أدوية الحموضة جميعها — لا أدوية حموضة — يرى النظام أن توقف الحموضة يأتي بتطبيق النظام لا بالأدوية.
- 来源状态
- 第三方网站（非官方）
- 归属
- Third-party site (unofficial by its own statement)
- 出处
- https://altayybat.com/ar/
- 归属的不确定性
- Lowest attribution level; the site states it is unofficial.
ممنوع أي أدوية كيميائية: خافض الحرارة، المسكنات، الفيتامينات، المكملات الصناعية، أدوية الحموضة، الأسبرين ويجب استشارة طبيبك الخاص وتحت اشرافه
- 来源状态
- 第三方网站（非官方）
- 归属
- Third-party site (unofficial by its own statement)
- 出处
- https://mytayibat.com/forbidden
- 归属的不确定性
- Lowest attribution level; the site states it is unofficial.
بص مثبطات الحموضه يا عبد الله في حد ذاتها سم قاتل يعني طالما مثبطات الحموضه بقت موجوده ا اعرف ا ان انت ا المرض جالك حرفيا
Look, Abdullah, acid suppressants are in themselves a deadly poison; as long as acid suppressants are there, I know that the disease has literally come to you.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا لايف حلو (打开来源)
- 发布日期
- 2026年3月29日
- 时间戳
- 0:11:45 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Close paraphrase ('poison').
كنت لوحدي بقول ممنوعه وبقول الكونترولوكس ممنوع وكنت لوحدي
I was alone saying they are forbidden, saying Controloc is forbidden, and I was alone.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! مقاومة الأنسولين ٢ (打开来源)
- 发布日期
- 2025年7月1日
- 时间戳
- 1:31:24 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Close paraphrase ('forbidden').
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
A permanent ban on all acid medicines for everyone.
2. 哪些内容可证实是正确的？
Overuse of PPIs without an indication is a real problem and guidelines recommend de-prescribing when there is no indication (see C-PPI-11).
3. 哪些内容是错误或夸大的？
A universal ban ignores proven indications in which PPIs prevent serious harm, including bleeding prevention in people on antiplatelet drugs and maintenance in Barrett's oesophagus or severe erosive oesophagitis (AGA 2022 BPA 4–7; Farrell 2017 excludes these groups from de-prescribing).
4. 哪些内容仍不明确？
Diet and weight loss can improve reflux symptoms, but how far they can replace drugs differs between patients.
5. 哪些研究支持该说法？
None for the universal ban.
6. 哪些研究与该说法相矛盾？
Scally 2018 meta-analysis of 849 RCTs (I-PPI-101); Omar 2026 RCT meta-analysis (I-PPI-113); COGENT (I-PPI-08); COMPASS GI (I-PPI-102: bleeding from gastroduodenal lesions HR 0.52); AspECT (I-PPI-09; high- vs low-dose esomeprazole with no PPI-free arm, benefit driven by mortality and high-grade dysplasia with no difference in adenocarcinoma, 40/1270 vs 41/1265); ACG 2022 (I-PPI-10); AGA 2017 (I-PPI-03); AGA 2022 (I-PPI-04); Farrell 2017 (I-PPI-05); NICE CG184 (I-GUT-108); NICE NG12 (I-GUT-109).
7. 对德国和欧洲而言情况如何？
German and European guidelines likewise reserve long-term PPI therapy for defined indications; over-the-counter PPIs are meant for short-term use.
8. 关于埃及的已知情况是什么？
Elawady states the ban applies to everyone; the mytayibat list adds advice to consult one's own doctor.
9. 合理的实际结论是什么？
PPI 只应在有明确理由时使用，并定期复查；但在多种疾病中，它们可以预防出血和并发症，未经医生指导不应停用。
评估详情
- 证据确定性的依据
High-certainty randomised evidence: a meta-analysis of 849 RCTs shows that PPIs reduce ulcer bleeding (OR 0.21, 99% CI 0.12-0.36) and help in acute bleeding (I-PPI-101); an RCT-only meta-analysis shows fewer clinically important upper GI bleeds with PPI prophylaxis (OR 0.51) without increased C. difficile or pneumonia (I-PPI-113); COGENT showed fewer GI bleeds with omeprazole on dual antiplatelet therapy (I-PPI-08); PPIs are strongly recommended for healing erosive oesophagitis (ACG 2022, high-quality evidence). AGA 2022, ACG 2022 and NICE CG184 name patients who should generally not stop PPIs. COMPASS GI shows that routine PPI gives little benefit in low-risk users (I-PPI-102), which supports deprescribing without an indication, not a universal ban.
- 来源质量
Archive quote, third-party food lists and several videos agree on a blanket ban; mytayibat adds 'under the supervision of your doctor'.
- 地区可推广性
Applies everywhere.
- 个体例外情况
No exception for bleeding ulcer, anticoagulation/antiplatelet therapy, Barrett's oesophagus, severe oesophagitis, eosinophilic oesophagitis, idiopathic pulmonary fibrosis or H. pylori eradication therapy is mentioned.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: Should all acid-suppressing medicines (PPIs and H2 blockers) be permanently forbidden for everyone, with heartburn treated only by diet?
研究问题详解 (PICO)
- 人群
- People with indications for acid suppression (bleeding risk on antithrombotics/NSAIDs, Barrett's, severe oesophagitis, stricture, ulcer bleeding)
- 干预或暴露
- PPI/H2RA
- 对照
- No acid suppression (diet only)
- 地域范围
- universal pharmacology
- 结局指标
- Upper GI bleeding
- Ulcer healing and recurrence
- Oesophagitis healing
- Mortality
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Routine acid blocker gave small benefit in low-risk heart patients
Moayyedi P et al.. Gastroenterology 2019 · PMID 31054846 · DOI 10.1053/j.gastro.2019.04.041 随机对照试验已核查摘要新增COMPASS GI: in low-risk patients on antithrombotics, routine pantoprazole did not reduce the composite of upper GI events (supports not giving PPIs routinely to low-risk people).
- 实际结果
- HR 0.88 (0.67-1.15); NNT about 1000 for bleeding lesions
- 方法学质量
- high (RCT)
- 相关性
- indirect support for restricting use, not for a ban
- 局限
- Low-risk population
哪些证据不支持该说法？
Acid blockers prevent bleeding ulcers in trials
Scally B et al.. Lancet Gastroenterol Hepatol 2018 · PMID 29475806 · DOI 10.1016/S2468-1253(18)30037-2 Meta分析已核查摘要新增Meta-analysis of 849 RCTs: PPIs strongly reduce ulcers and ulcer bleeding and help in acute bleeding.
- 实际结果
- Bleeding OR 0.40 overall, PPI 0.21 (99% CI 0.12-0.36)
- 方法学质量
- high
- 相关性
- direct
- 局限
- Small-study bias possible; no mortality reduction
Omeprazole prevents bleeding with dual antiplatelet therapy
COGENT RCT: omeprazole reduced GI bleeding with dual antiplatelet therapy.
- 实际结果
- HR 0.34; overt bleeding HR 0.13 (packet)
- 方法学质量
- high
- 相关性
- direct
- 局限
- Stopped early
Randomised trials: PPIs prevent bleeding without clear infection increase
RCT meta-analysis: PPI prophylaxis reduced clinically important upper GI bleeding without increasing CDI or pneumonia.
- 实际结果
- OR 0.51 (0.27-0.94)
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Few trials
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
A universal ban is contradicted by high-certainty randomised evidence of benefit in defined indications; the correct core is that PPIs are overused and should be reviewed and deprescribed when no indication exists.
为什么有些研究权重更大
Large RCT meta-analyses and guidelines dominate; COMPASS GI shows that benefit depends on baseline risk.
因果关系是否已确立？ 是，已确立 RCTs show prevention of bleeding and healing of ulcers/oesophagitis.
仍存在的不确定性
None for the main conclusion.
合理的结论
False.
为什么研究结果看起来互相矛盾？
COMPASS GI (no composite benefit in low-risk users) vs Scally/COGENT (large benefit): differ in baseline bleeding risk; together they support targeted, not universal, use.
这是否取决于国家？
- 一般生物学效应
- Pharmacology of PPIs is the same in Egypt and Europe.
- 饮食习惯
- Not decisive.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant (except ranitidine NDMA impurities, C-PPI-08).
- 本国生产条件
- Generic products are used in both regions; no evidence of different pharmacological effects.
- 法律规则
- PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
- 实际监测数据
- No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Absolute effect of routine PPI – Composite 1.16% vs 1.32%; ARR 0.16 points; NNT about 640; post-hoc bleeding NNT 982 已重新计算
- Log-symmetry of ORs – All consistent 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Upper GI bleeding prevention with PPIs in at-risk people
- 起始等级
- 高（随机试验）
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- AGA (American Gastroenterological Association): AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review (Targownik LE et al., Gastroenterology 2022; I-PPI-04) (2022) · 原始文献
Best Practice Advice read verbatim in the PubMed record: regular review and documentation of the indication (BPA 1); trial of de-prescribing for all without a definitive indication (BPA 2); complicated GERD (severe erosive oesophagitis, oesophageal ulcer, peptic stricture) generally not for discontinuation (BPA 4); Barrett's oesophagus, eosinophilic oesophagitis, idiopathic pulmonary fibrosis generally not for de-prescribing (BPA 5); assess upper GI bleeding risk first and do not de-prescribe in high-risk patients (BPA 6-7); warn about transient rebound symptoms (BPA 8); tapering or abrupt stop both possible (BPA 9); decide on indication, not on fear of PPI-associated adverse events (BPA 10). The publisher page could not be fetched (HTTP 403). - ACG (American College of Gastroenterology): ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO et al. 2022; I-PPI-10) (2022) · 原始文献
Full text read: weight loss recommended for overweight/obese patients (strong, moderate evidence); avoid meals within 2-3 h of bedtime, avoid tobacco, avoid 'trigger foods', elevate head of bed for nocturnal symptoms (conditional, low evidence); Table 3 rates 'avoid carbonated beverages' as moderate evidence and recommendable; PPIs over H2RAs for healing erosive oesophagitis (strong, high evidence); attempt to discontinue PPIs in patients without erosive oesophagitis or Barrett's whose symptoms resolved (conditional, low); maintenance PPI indefinitely or surgery for LA grade C/D oesophagitis (strong, moderate); endoscopy first for dysphagia or alarm symptoms (weight loss, GI bleeding); rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking. - NICE: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184; I-GUT-108) (2014, updated 2019) · 原始文献
Lifestyle advice (healthy eating, weight reduction, smoking cessation; avoid personal precipitants; main meal well before bed); step down PPIs to lowest effective dose or as-needed unless an underlying condition or comedication needs continuing treatment; same-day referral for dyspepsia with significant acute GI bleeding; long-term full-dose PPI after oesophageal stricture dilatation and as maintenance for severe oesophagitis; H. pylori eradication for H. pylori-positive peptic ulcer; PPI co-prescription with NSAIDs in high-risk people. - NICE: Suspected cancer: recognition and referral (NG12), upper GI section (I-GUT-109) (2015, page updated April 2026) · 原始文献
Suspected cancer pathway referral for dysphagia, or age 55+ with weight loss plus upper abdominal pain, reflux or dyspepsia; consider endoscopy for haematemesis and for age 55+ with treatment-resistant dyspepsia or upper abdominal pain with low haemoglobin.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (gastroprotect* OR "proton pump inhibitor") AND ("peptic ulcer" OR "upper gastrointestinal bleeding") AND (aspirin OR NSAID OR antiplatelet OR anticoagulant) AND ("meta-analysis" OR "randomised" OR "randomized") AND PUB_YEAR:[2015 TO 2026] | 反对性证据 | 1453 | |
| Europe PMC | 2026年10月26日 | TITLE:"gastroprotectant drugs" AND peptic ulcer | 反对性证据 | 1 | |
| Europe PMC | 2026年10月26日 | TITLE:"pantoprazole" AND TITLE:"rivaroxaban" AND gastroduodenal | 双向 | 2 | |
| PubMed (E-utilities esearch) | 2026年10月26日 | (proton pump inhibitors[mh]) AND (gastrointestinal hemorrhage[mh]) AND (anticoagulants[mh] OR platelet aggregation inhibitors[mh] OR anti-inflammatory agents, non-steroidal[mh]) AND randomized controlled trial[pt] | 反对性证据 | 21 | |
| PubMed (E-utilities esearch) | 2026年10月26日 | (proton pump inhibitors[mh]) AND (barrett esophagus[mh]) AND (randomized controlled trial[pt] OR guideline[pt]) | 反对性证据 | 37 | |
| PubMed efetch (record of PMID 35183361) | 2026年10月26日 | efetch id=35183361 (AGA 2022 de-prescribing BPA statements); publisher page attempted via WebFetch returned HTTP 403 | 指南 | 1 | |
| Web (curl/WebFetch of guideline page) | 2026年10月26日 | https://pmc.ncbi.nlm.nih.gov/articles/PMC8754510/ (ACG 2022 GERD guideline full text; Europe PMC fullTextXML returned HTTP 500) | 指南 | 1 | |
| Web (curl/WebFetch of guideline page) | 2026年10月26日 | https://www.nice.org.uk/guidance/cg184/chapter/1-Recommendations | 指南 | 1 | |
| Web (curl/WebFetch of guideline page) | 2026年10月26日 | https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer | 指南 | 1 |
待解决的问题
None.
核查深度如何？
11 项相关研究：4 项核查了全文（其中 1 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 错误 (中) → 错误 (高)
Certainty raised: the 849-trial meta-analysis and an RCT-only meta-analysis provide high-certainty evidence of bleeding prevention; guidelines (AGA 2022, ACG 2022, NICE CG184) consistently identify patients who should not stop.
新来源: I-PPI-101 I-PPI-102 I-PPI-113 I-GUT-108 I-GUT-109
通俗解释
许多人服用抑酸药的时间超过了需要，对此进行复查是明智的。但对某些人来说，这些药物具有保护作用，例如服用抗凝药或抗血小板药并有胃出血风险的人、有重度食管炎症的人，以及患有 Barrett 食管的人。随机对照试验显示，这类患者出血更少。因此，对所有人禁止可能造成伤害。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (11)
-
Omeprazole prevents bleeding with dual antiplatelet therapy
Bhatt DL et al.. N Engl J Med 2010 · PMID 20925534 · DOI 10.1056/NEJMoa1007964随机对照试验独立交叉核查已核查摘要★ 关键研究GI events fell from 2.9% to 1.1% with omeprazole.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Prevent GI bleeding.
- 研究是如何开展的？
RCT.
- 研究了多少人、动物或样本？
3,761.
- 实际发现了什么？
Fewer GI events.
- 观察到的效应有多大？
HR 0.34.
- 研究结果对日常生活意味着什么？
PPIs protect high-risk patients.
- 该研究有哪些局限？
Early stop; industry.
- 它对 Elawady 的具体说法说明了什么？
Contradicts universal ban.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
Barrett's oesophagus: high-dose PPI improves outcomes
Jankowski JAZ et al.. Lancet 2018 · PMID 30057104 · DOI 10.1016/S0140-6736(18)31388-6随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究Over about 9 years, high-dose esomeprazole improved a composite of death, cancer and severe dysplasia.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Barrett's chemoprevention.
- 研究是如何开展的？
RCT.
- 研究了多少人、动物或样本？
2,557.
- 实际发现了什么？
Benefit for high dose.
- 观察到的效应有多大？
TR 1.27; NNT 34.
- 研究结果对日常生活意味着什么？
PPIs help people with Barrett's.
- 该研究有哪些局限？
No placebo; open label.
- 它对 Elawady 的具体说法说明了什么？
Contradicts universal ban.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
ACG 2022 reflux guideline
Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538指南 / 立场声明独立交叉核查已核查全文★ 关键研究Weight loss, avoiding late meals and trigger foods help; PPIs are best for erosive oesophagitis.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
GERD management.
- 研究是如何开展的？
Guideline.
- 实际发现了什么？
Lifestyle + PPI recommendations.
- 研究结果对日常生活意味着什么？
Diet helps; drugs needed for erosive disease.
- 该研究有哪些局限？
Low evidence for some lifestyle advice.
- 它对 Elawady 的具体说法说明了什么？
Mixed for diet claims; contradicts ban.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
AGA advice on long-term PPIs
Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031指南 / 立场声明独立交叉核查已核查摘要PPIs are justified for defined indications; risks do not require routine monitoring.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Risk–benefit guidance.
- 研究是如何开展的？
Expert review.
- 实际发现了什么？
10 best practice statements.
- 研究结果对日常生活意味着什么？
Use for real indications at lowest dose.
- 该研究有哪些局限？
Expert opinion.
- 它对 Elawady 的具体说法说明了什么？
Mixed: supports indication-based use.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
How to stop PPIs safely (AGA 2022)
Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247指南 / 立场声明独立交叉核查已核查摘要★ 关键研究Stop PPIs without a definite indication; keep them in Barrett's, severe oesophagitis and high bleeding risk; expect temporary rebound.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
De-prescribing guidance.
- 研究是如何开展的？
Expert review.
- 实际发现了什么？
10 statements.
- 研究结果对日常生活意味着什么？
Many people can stop; some must not.
- 该研究有哪些局限？
Expert opinion.
- 它对 Elawady 的具体说法说明了什么？
Supports overuse claim; contradicts universal ban and 'cannot stop'.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
Canadian guideline for stopping PPIs
Farrell B et al.. Can Fam Physician 2017 · PMID 28500192指南 / 立场声明独立交叉核查已核查摘要PPIs can be reduced or stopped in many patients, but not in Barrett's, severe oesophagitis or after bleeding ulcers.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Deprescribing.
- 研究是如何开展的？
GRADE guideline.
- 实际发现了什么？
Deprescribe eligible patients.
- 研究结果对日常生活意味着什么？
Stopping is possible.
- 该研究有哪些局限？
Abstract only.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'cannot stop' and universal ban.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
Acid blockers prevent bleeding ulcers in trials
Scally B et al.. Lancet Gastroenterol Hepatol 2018 · PMID 29475806 · DOI 10.1016/S2468-1253(18)30037-2Meta分析独立交叉核查已核查摘要★ 关键研究Across 849 randomised trials, acid-suppressing drugs, especially PPIs, strongly reduced ulcers and ulcer bleeding.
PPIs reduce ulcer bleeding (OR 0.21) and rebleeding
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Summarise all trials of stomach-protecting drugs.
- 研究是如何开展的？
Meta-analysis of 849 RCTs.
- 研究了多少人、动物或样本？
142,485 participants.
- 实际发现了什么？
Ulcers and bleeding fell markedly; deaths not significantly.
- 观察到的效应有多大？
Bleeding OR 0.40 overall; PPI 0.21.
- 研究结果对日常生活意味着什么？
For people at risk, PPIs prevent dangerous bleeding.
- 该研究有哪些局限？
Many small, short trials.
- 它对 Elawady 的具体说法说明了什么？
Contradicts a universal ban on acid blockers.
- 研究结果是否适用于德国和欧洲？
Applies everywhere.
- 从该研究中明确不能得出什么结论？
Does not show everyone benefits; low-risk users gain little.
-
Routine acid blocker gave small benefit in low-risk heart patients
Moayyedi P et al.. Gastroenterology 2019 · PMID 31054846 · DOI 10.1053/j.gastro.2019.04.041随机对照试验独立交叉核查已核查摘要★ 关键研究In 17,598 heart patients on aspirin or a blood thinner, pantoprazole halved bleeding from stomach lesions but did not reduce all stomach problems combined; about 1000 needed treatment to prevent one bleed.
Pantoprazole halved bleeding from gastroduodenal lesions
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test routine PPI in heart patients on blood thinners.
- 研究是如何开展的？
Double-blind RCT.
- 研究了多少人、动物或样本？
17,598 patients.
- 实际发现了什么？
No effect on composite; fewer bleeding lesions.
- 观察到的效应有多大？
HR 0.88 composite; 0.52 bleeding lesions.
- 研究结果对日常生活意味着什么？
Benefit depends on bleeding risk; low-risk people gain little.
- 该研究有哪些局限？
Low event rates.
- 它对 Elawady 的具体说法说明了什么？
Supports reviewing 'protective' PPIs, contradicts a universal ban.
- 研究结果是否适用于德国和欧洲？
Applies to Europe.
- 从该研究中明确不能得出什么结论？
Not about high-risk patients with prior bleeding.
-
Randomised trials: PPIs prevent bleeding without clear infection increase
Omar MA et al.. J Clin Med 2026 · PMID 41976918 · DOI 10.3390/jcm15072617Meta分析独立交叉核查已核查摘要★ 关键研究In 8 randomised trials with 30,019 people, PPIs reduced serious stomach bleeding and did not significantly increase pneumonia or C. difficile.
Upper GI bleeding OR 0.51 (0.27-0.94)
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Check infection risks of PPIs in RCTs.
- 研究是如何开展的？
Meta-analysis of RCTs.
- 研究了多少人、动物或样本？
30,019 participants.
- 实际发现了什么？
No significant rise in CDI or pneumonia; less bleeding.
- 观察到的效应有多大？
Pneumonia OR 1.00; CDI 1.29; bleeding 0.51.
- 研究结果对日常生活意味着什么？
Short-term PPI prophylaxis is relatively safe when indicated.
- 该研究有哪些局限？
Few trials; rare events imprecise.
- 它对 Elawady 的具体说法说明了什么？
Limits claims of pneumonia; leaves CDI uncertain.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot exclude small long-term risks.
-
UK guideline on heartburn and indigestion
National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)指南 / 立场声明独立交叉核查已核查全文★ 关键研究NICE advises lifestyle changes and the lowest effective dose of acid blockers, but long-term full-dose treatment for severe inflammation or a narrowed gullet.
Long-term full-dose PPI for stricture/severe oesophagitis; PPI with NSAIDs in high-risk
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide care of reflux and indigestion.
- 研究是如何开展的？
National guideline.
- 研究了多少人、动物或样本？
Adults in England.
- 实际发现了什么？
Lifestyle first; step down PPIs; keep PPIs for stricture/severe oesophagitis; eradicate H. pylori in ulcers.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Diet matters, but some people need acid blockers long term.
- 该研究有哪些局限？
Older evidence base for some statements.
- 它对 Elawady 的具体说法说明了什么？
Contradicts a blanket ban on acid blockers.
- 研究结果是否适用于德国和欧洲？
Applies directly to Europe.
- 从该研究中明确不能得出什么结论？
Not an evidence synthesis for each claim.
-
Warning signs that need a doctor
National Institute for Health and Care Excellence (NICE). NICE guideline NG12 2015 (last updated 15 April 2026)指南 / 立场声明独立交叉核查已核查全文Difficulty swallowing, vomiting blood, or weight loss with reflux at 55 or older should be checked for cancer.
Alarm symptoms require medical assessment
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Define when to suspect upper GI cancer.
- 研究是如何开展的？
National guideline.
- 研究了多少人、动物或样本？
Adults in primary care.
- 实际发现了什么？
Dysphagia, weight loss, haematemesis and anaemia trigger referral or endoscopy.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Such symptoms must be checked, not treated by diet alone.
- 该研究有哪些局限？
UK thresholds.
- 它对 Elawady 的具体说法说明了什么？
Supports the safety warning.
- 研究结果是否适用于德国和欧洲？
Applies to Europe.
- 从该研究中明确不能得出什么结论？
Not about diet efficacy.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (0)
该组中没有研究。
地区背景
德国 / 欧盟
German and European guidelines likewise reserve long-term PPI therapy for defined indications; over-the-counter PPIs are meant for short-term use.
埃及
Elawady states the ban applies to everyone; the mytayibat list adds advice to consult one's own doctor.
在我的国家适用什么？
一般科学评估
错误 这一说法是错误的：PPI 存在过度使用，但在特定疾病中它们可以预防严重出血和并发症，对所有人禁止可能造成伤害。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Clopidogrel with or without omeprazole in coronary artery disease.. Bhatt DL et al.. N Engl J Med 2010 · PMID 20925534 · DOI 10.1056/NEJMoa1007964
- Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.. Jankowski JAZ et al.. Lancet 2018 · PMID 30057104 · DOI 10.1016/S0140-6736(18)31388-6
- ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.. Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538
- The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247
- Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.. Farrell B et al.. Can Fam Physician 2017 · PMID 28500192
- Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.. Scally B et al.. Lancet Gastroenterol Hepatol 2018 · PMID 29475806 · DOI 10.1016/S2468-1253(18)30037-2
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31054846 · DOI 10.1053/j.gastro.2019.04.041
- Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of Clostridioides difficile Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs.. Omar MA et al.. J Clin Med 2026 · PMID 41976918 · DOI 10.3390/jcm15072617
- Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NICE guideline CG184). National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)
- Suspected cancer: recognition and referral (NICE guideline NG12), section 1.2 upper gastrointestinal tract cancers. National Institute for Health and Care Excellence (NICE). NICE guideline NG12 2015 (last updated 15 April 2026)